You could argue that overall we’re seeing either no benefit or some benefit here, which is good
As expected, no blockbuster. There are concerns about patient recruitment and endpoints as well. We'll have to wait for antivirals.
As expected, no blockbuster. There are concerns about patient recruitment and endpoints as well. We'll have to wait for antivirals.